News

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The FDA has approved Grifols’ new formulation of immune globulin (GamaSTAN) for hepatitis A virus and measles post-exposure prophylaxis.

A Legionnaires’ disease outbreak in New Hampshire has been linked to at least 1 resort in the town of Hampton.

Do ancient medicinal treatments hold potential for future antimicrobial efforts?

New research finds that the flu vaccine is more successful in women than in men, but the complexity of the issue makes it difficult to know exactly why that is.

Strands of hair have several advantages over plasma samples in revealing whether a person with HIV is adhering to a medication regimen.

Ebola is not the only infectious disease that health officials in the Democratic Republic of the Congo are struggling with.

The conventional approach to fighting resistant E coli infections typically involves the use of no more than 2 antibiotics; however, combining as many as 5 may be the trick to fighting these infections.

Investigators have found that a strain of E coli found in retail poultry products can cause a wide range of infections in people.

New practical advice for the treatment of C difficile from SHEA advises against routine testing in NICU patients with diarrhea.

Tick-borne infections will pose significant threats in the near future, according to infectious disease experts.

Investigators find that only 48% of surveyed health care providers had ever prescribed PrEP.

Although the incidence of Chlamydia trachomatis infections remains high among young women (ages 14-24), new data indicate that prevalence of the sexually-transmitted infection is decreasing.

A new study has uncovered how cytomegalovirus can bypass the body’s defense mechanisms that prevent viral infections.

Study results indicate that patients with HIV are willing to wait at least 19 hours or travel up to 28 miles to see a “nice” provider.

Investigators find telavancin has potent in vitro activity and low resistance development potential when used against S aureus isolates in patients with cystic fibrosis.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Investigators from Loyola Medicine have developed a 3-pronged model that could identify patients at risk for acute respiratory distress syndrome.

Rezafungin, an investigational antifungal, demonstrated significant activity against Aspergillus in an in vitro study.

CDC Antibiotic Resistance Laboratory Network has launched a pilot program using printers with antibiotic susceptibility testing panels.

The FDA has approved 2 new treatments for HIV: a once-daily fixed-dose combination tablet of doravirine, lamivudine, and tenofovir disoproxil fumarate; and doravirine, a new NNRTI to be administered in combination with other antiretroviral medicines.

A new study by St. Jude Children’s Research Hospital reported that gamma delta (γδ) T cells play a key role in protecting infants from flu complications.

The National Emerging Infectious Disease Laboratories at Boston University have the latest equipment, security redundancies, and airtight procedures and protocols. Yet, as they begin work on Ebola and Marburg, they cannot eliminate the risk of human error.

A new analysis from the CDC shows steep and sustained increases in STDs in recent years.

The CDC has announced an investigation of a multistate outbreak of Salmonella I 4,[5],12:i:- infections that have been linked with kosher chicken.

A social media campaign initiated in Russia may be sowing the seeds of debate surrounding vaccine safety, causing new outbreaks of measles globally.

West Virginia’s Bureau for Public Health has requested the assistance from the CDC to contain the statewide hepatitis A outbreak.

Additional evidence supports the use of oritavancin as a cost-saving outpatient treatment for acute bacterial skin and skin structure infections (ABSSTIs) in patients who would otherwise be admitted to the hospital for therapy.